Download
s10585-020-10055-x.pdf 7,43MB
WeightNameValue
1000 Titel
  • Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells
1000 Autor/in
  1. Kovalchuk, Bogdana |
  2. Berghoff, Anna S. |
  3. Karreman, Matthia A. |
  4. Frey, Katharina |
  5. Piechutta, Manuel |
  6. Fischer, Manuel |
  7. Grosch, Julia |
  8. Heiland, Sabine |
  9. Breckwoldt, Michael O. |
  10. Hilberg, Frank |
  11. Wick, Wolfgang |
  12. Winkler, Frank |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-09-12
1000 Erschienen in
1000 Quellenangabe
  • 37(6):637-648
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s10585-020-10055-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666285/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Brain metastases (BM) are an ever-increasing challenge in oncology, threatening quality of life and survival of many cancer patients. The majority of BM originate from lung adenocarcinoma, and stage III patients have a risk of 40-50% to develop BM in the first years of disease onset. As therapeutic options are limited, prevention of their occurrence is an attractive concept. Here we investigated whether Nintedanib (BIBF 1120), a tyrosine kinase inhibitor (TKI) targeting the VEGF pathway approved for lung adenocarcinoma, and the dual anti-VEGF-A/Ang2 nanobody BI836880 have the potential to prevent BM formation. A mouse model of brain metastasis from lung adenocarcinoma was used in which tumor cells were injected intracardially. Metastases formation occurred inside and outside of the brain and was followed by MRI, IVIS, and immunohistochemistry. BM were reduced in volume and number by both Nintedanib and the dual anti-VEGF-A/Ang2 nanobody, which translated into improved survival. Both compounds were able to normalize cerebral blood vessels at the site of brain metastatic lesions. Extracranial metastases, however, were not reduced, and meningeal metastases only partially. Interestingly, unspecific control IgG also lead to brain vessel normalization and reduction of brain and meningeal metastases. This data indicates a brain-specific group effect of antiangiogenic compounds with respect to metastasis prevention, most likely by preventing an early angiogenic switch. Thus, Nintedanib and BI836880 are promising candidates for future BM preventive study concepts in lung adenocarcinoma patients.
1000 Sacherschließung
lokal Cell Line, Tumor [MeSH]
lokal Immunoglobulin G/administration
lokal Male [MeSH]
lokal Xenograft Model Antitumor Assays [MeSH]
lokal Ang-2
lokal Brain Neoplasms/prevention
lokal Single-Domain Antibodies/immunology [MeSH]
lokal Vascular Endothelial Growth Factor A/immunology [MeSH]
lokal Lung adenocarcinoma
lokal Xenograft metastasis model
lokal Brain neoplasms
lokal Anti-angiogenic drugs
lokal Adenocarcinoma of Lung/therapy [MeSH]
lokal Adenocarcinoma of Lung/drug therapy [MeSH]
lokal Brain Neoplasms/secondary [MeSH]
lokal Angiogenesis Inhibitors/administration
lokal Humans [MeSH]
lokal Therapeutic IgG
lokal Vascular Endothelial Growth Factor A/antagonists
lokal Adenocarcinoma of Lung/immunology [MeSH]
lokal Mice, Inbred NOD [MeSH]
lokal Cancer prevention
lokal Animals [MeSH]
lokal Mice, SCID [MeSH]
lokal Vesicular Transport Proteins/immunology [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Research Paper
lokal Brain Neoplasms/blood supply [MeSH]
lokal Indoles/administration
lokal Mice [MeSH]
lokal Single-Domain Antibodies/administration
lokal VEGF-A
lokal Vesicular Transport Proteins/antagonists
lokal Adenocarcinoma of Lung/pathology [MeSH]
lokal Brain Neoplasms/therapy [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S292YWxjaHVrLCBCb2dkYW5h|https://frl.publisso.de/adhoc/uri/QmVyZ2hvZmYsIEFubmEgUy4=|https://frl.publisso.de/adhoc/uri/S2FycmVtYW4sIE1hdHRoaWEgQS4=|https://frl.publisso.de/adhoc/uri/RnJleSwgS2F0aGFyaW5h|https://frl.publisso.de/adhoc/uri/UGllY2h1dHRhLCBNYW51ZWw=|https://frl.publisso.de/adhoc/uri/RmlzY2hlciwgTWFudWVs|https://frl.publisso.de/adhoc/uri/R3Jvc2NoLCBKdWxpYQ==|https://frl.publisso.de/adhoc/uri/SGVpbGFuZCwgU2FiaW5l|https://frl.publisso.de/adhoc/uri/QnJlY2t3b2xkdCwgTWljaGFlbCBPLg==|https://frl.publisso.de/adhoc/uri/SGlsYmVyZywgRnJhbms=|https://frl.publisso.de/adhoc/uri/V2ljaywgV29sZmdhbmc=|https://orcid.org/0000-0003-4892-6104
1000 Hinweis
  • DeepGreen-ID: d463a798f0334333b152542aabf7c0be ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6468310.rdf
1000 Erstellt am 2023-11-17T15:36:23.886+0100
1000 Erstellt von 322
1000 beschreibt frl:6468310
1000 Zuletzt bearbeitet 2023-12-01T07:41:34.989+0100
1000 Objekt bearb. Fri Dec 01 07:41:34 CET 2023
1000 Vgl. frl:6468310
1000 Oai Id
  1. oai:frl.publisso.de:frl:6468310 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source